BioLineRx is trading at $2.12, up 5.47%, with no confirmed company-specific catalyst identified for the October 19 pre-market move. - BioLineRx’s investor-relations page lists October 8 as its latest press release. - A patent-allowance announcement surfaced for October 16, extending U.S. motixafortide patent protection through December 2041; no source connects it to the gain. - Broader market signals are mixed, and the biotech ETF is down pre-market, offering no clear explanation for the rise.